-- 根據FactSet調查的分析師報告，Edgewise Therapeutics (EWTX) 的平均評級為“買入”，平均目標價為42.75美元。 （報道北美、亞洲和歐洲主要銀行及研究機構的股票、商品和經濟研究。研究機構可透過以下連結聯絡我們：https://www..com/contact-us）
Price: $37.70, Change: $-0.31, Percent Change: -0.82%
Related Articles
Research
Research Alert: CFRA Maintains Hold Opinion On Lucid Group Inc.
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lower our 12-month target to $6 from $10. Following a weaker-than-expected Q1 earnings release, we are maintaining a Hold opinion on LCID shares. We revise our adjusted EPS estimates to -$12.00 from -$12.70 for '26 and to -$11.10 from -$11.45 for '27. LCID posted Q1 adjusted EPS of -$2.82 vs. -$2.04, well short of the -$2.30 consensus. Revenue rose 20% to $282.5M ($76.0M below consensus) in Q1, led by higher prices, as total vehicle sales fell 1% to 3,093 units. In the release, LCID did not provide any update regarding prior 2026 vehicle production guidance of 25K-27K units (an implied increase over the 17,840 units produced in 2025). In our view, LCID's accelerating cash burn and rising inventories suggest ongoing risks. The company's ability to achieve sustainable growth while managing its substantial cash requirements remains the critical challenge as it seeks to establish a viable position in the competitive luxury EV market; however, a $1.5B capital raise last month helps extend its liquidity runway.
$LCID
Research
Research Alert: CFRA Maintains Sell Opinion On Shares Of Celanese Corporation
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:After reviewing Q1 earnings, we raise our 12-month target price by $2 to $43 on a forward P/E of 7.4x our 2027 EPS view of $5.78, a discount to the three-year average of 10.4x justified by CE's high debt levels and subdued demand. We raise our 2026 EPS view by $1.35 to $6.14 and decrease 2027's by $0.09 to 5.78. Our sales estimates are $9.7 billion for 2026 and $10.1 billion for 2027. On the positive side, CE's Acetyl Chain's Q2 2026 Adjusted EBIT guidance of $300M-$325M was solid, led by higher expected volumes and prices. However, the acetate tow business remains weak and feedstock costs have risen sharply. Meanwhile, Engineered Materials' Q2 2026 Adjusted EBIT guidance of $190M-$210M was more conservative due to inventory reductions and additional costs from the POM facility turnaround. Overall, we believe CE's 48% year-to-date stock gain is excessive and expect earnings to decline once again in 2027 as the temporary margin boost from the Middle East conflict fades.
$CE
Treasury
Canada's Provincial Budgets in Pain From Healthcare Costs, Says CIBC
The COVID-19 pandemic may be distant in the rearview mirror, but healthcare costs in Canada are continuing to have an outsized impact on provincial finances, said CIBC.At just over 40% of total expenses in aggregate, healthcare is always the single biggest line item, writes the bank in a note to clients. However, its recent impact has been even greater than that, as it has contributed more than half of the increases in spending seen in the past five years.In addition, these cost increases haven't always been easy to predict, with healthcare also contributing more than 50% of recent spending overshoots relative to initial budget estimates, points out CIBC.Increased health spending needs have often been blamed on inflation, including pay increases for medical staff and population growth. While concerns about inflationary pressures are resurfacing again due to the Middle East conflict, the sharp deceleration in population growth should, in theory, ease the strain on healthcare costs.Unfortunately, however, there is another and potentially larger factor driving costs upwards, one that will get worse before it gets better. That's the increase in healthcare costs that comes from an aging population, as per capita health spending rises exponentially for age brackets above 65, states the bank.If the population continues to age as expected, then healthcare costs could continue to rise more than provinces, on aggregate, are currently projecting, according to CIBC.
$$CXY